These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 8985472)

  • 21. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
    Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA
    Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
    Tada M; Shirakawa K; Matsuoka N; Mutoh S
    Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
    Dolzan V; Serretti A; Mandelli L; Koprivsek J; Kastelic M; Plesnicar BK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1562-6. PubMed ID: 18573584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():23-7. PubMed ID: 9766616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of cognition in the risk--benefit and safety analysis of antipsychotic medication.
    Borison RL
    Acta Psychiatr Scand Suppl; 1996; 389():5-11. PubMed ID: 8985471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol.
    Oosthuizen PP; Emsley RA; Maritz JS; Turner JA; Keyter N
    J Clin Psychiatry; 2003 Sep; 64(9):1075-80. PubMed ID: 14628983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Memory impairment in schizophrenia: perspectives from psychopathology and pharmacotherapy.
    Stip E
    Can J Psychiatry; 1996 Oct; 41(8 Suppl 2):S27-34. PubMed ID: 8899248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Managing antipsychotic-induced acute and tardive dystonia.
    Raja M
    Drug Saf; 1998 Jul; 19(1):57-72. PubMed ID: 9673858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risperidone in the treatment of psychosis and concomitant buccolinguomasticatory dyskinesia in the elderly.
    Koponen HJ
    Int J Geriatr Psychiatry; 1997 Mar; 12(3):412-3. PubMed ID: 9152730
    [No Abstract]   [Full Text] [Related]  

  • 31. Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons.
    Haddad PM; Das A; Keyhani S; Chaudhry IB
    J Psychopharmacol; 2012 May; 26(5 Suppl):15-26. PubMed ID: 22057019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [New chemotherapy approaches to psychoses].
    Olié JP; Baylé FJ
    Encephale; 1997 Apr; 23 Spec No 2():2-9. PubMed ID: 9273302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Movement disorders associated with neuroleptic treatment.
    Wirshing WC
    J Clin Psychiatry; 2001; 62 Suppl 21():15-8. PubMed ID: 11584982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risperidone in acute and long-term therapy of schizophrenia--a clinical profile.
    Pajonk FG
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):15-23. PubMed ID: 14687852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Gaebel W; Riesbeck M; Wölwer W; Klimke A; Eickhoff M; von Wilmsdorff M; Jockers-Scherübl MC; Kühn KU; Lemke M; Bechdolf A; Bender S; Degner D; Schlösser R; Schmidt LG; Schmitt A; Jäger M; Buchkremer G; Falkai P; Klingberg S; Köpcke W; Maier W; Häfner H; Ohmann C; Salize HJ; Schneider F; Möller HJ;
    J Clin Psychiatry; 2007 Nov; 68(11):1763-74. PubMed ID: 18052570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
    Bai YM; Yu SC; Lin CC
    J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antipsychotic-induced extrapyramidal syndromes. Risperidone compared with low- and high-potency conventional antipsychotic drugs.
    Schillevoort I; de Boer A; Herings RM; Roos RA; Jansen PA; Leufkens HG
    Eur J Clin Pharmacol; 2001 Jul; 57(4):327-31. PubMed ID: 11549212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Algorithms for neuroleptic-associated tardive movement disorders.
    Akiyama K
    Psychiatry Clin Neurosci; 1999 Oct; 53 Suppl():S23-9. PubMed ID: 10560894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.